for people ages 18 years and up (full criteria)
at Orange, California and other locations
study started
completion around



This study is researching an experimental drug called odronextamab, referred to as study drug, when used in combination with chemotherapy. The study is focused on patients with diffuse large B-cell lymphoma (DLBCL) that have not been treated before (called "previously untreated"), have come back after treatment (called "relapsed"), or have not responded to treatment (called "refractory").

This study will be made up of Part 1a, Part 1b, and Part 2.The aim of Part 1a and Part 1b of the study is to see how safe and tolerable the study drug in combination with chemotherapy is and to determine the dose and schedule of the study drug to be combined with chemotherapy in Part 2 of the study.

The aim of Part 2 of the study is to see how effective the combination of the study drug with chemotherapy is in comparison with the combination of rituximab and chemotherapy, the current standard of care treatment approved for Non-Hodgkin's lymphoma (NHL). Standard of care means the usual medication expected and used when receiving treatment for a condition.

The study is looking at several other research questions, including:

  • What side effects may happen from taking the study drug when combined with chemotherapy
  • How much study drug is in your blood at different times
  • Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
  • The impact from the study drug on your quality of life and ability to complete routine daily activities

Official Title

A Phase 3, Open Label, Randomized Study Comparing the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 × Anti-CD3 Bispecific Antibody, in Combination With CHOP (O-CHOP) Versus Rituximab in Combination With CHOP (R-CHOP) in Previously Untreated Participants With Diffuse Large B-cell Lymphoma (DLBCL) (OLYMPIA-3)


Diffuse Large B-cell Lymphoma (DLBCL), Non-Hodgkin lymphomas (NHL), B-cell non-Hodgkin lymphomas (B-NHL), Diffuse Large B-cell Lymphoma, Odronextamab, Anti-CD20 × anti-CD3 bispecific antibody, Lymphoma, B-Cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Prednisone, Prednisolone, Cyclophosphamide, Rituximab, Doxorubicin, Vincristine, Prednisone/Prednisolone, Odronextamab + CHOP, Rituximab + CHOP


You can join if…

Open to people ages 18 years and up

  1. Previously untreated participants for lymphoma with documented cluster of differentiation 20+ (CD20+) DLBCL, as described in the protocol OR relapsed or refractory DLBCL (Part 1A only)
  2. Measurable disease with at least one nodal lesion or at least one extranodal lesion, as described in the protocol
  3. Eastern Cooperative Oncology Group (ECOG) performance status ≤2
  4. Life expectancy ≥ 12 months
  5. International Prognostic Index (IPI) of 3 to 5 (part 1 only) and ≥2 (part 2) for untreated DLBCL only;
  6. Adequate hematologic and organ function, as defined in the protocol.

You CAN'T join if...

  1. Primary central nervous system (CNS) lymphoma or known involvement by non-primary CNS NHL and history or current relevant CNS pathology
  2. Another active malignancy, significant active disease or medical condition, as described in the protocol
  3. Peripheral neuropathy Grade ≥3
  4. Treatment with any systemic anti-lymphoma therapy
  5. Any investigational therapy within 28 days or 5 half-lives of the drug, whichever is shorter, prior to the start of study treatment
  6. Recent major surgery, prior organ transplantation, or standard radiotherapy, as described in the protocol
  7. Allergy/hypersensitivity to study drugs, as described in the protocol
  8. Infections such as any active infection (bacterial, viral, fungal, mycobacterial, parasitic or other), active Coronavirus disease (COVID-19) infection, uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV), Cytomegalovirus (CMV) infection, as described in the protocol.

    Note: Other protocol-defined Inclusion/ Exclusion criteria apply


  • UC Irvine Health Chao Family Comprehensive Cancer Cente accepting new patients
    Orange California 92868 United States
  • The Community Cancer Trials accepting new patients
    Ogden Utah 84405 United States


accepting new patients
Start Date
Completion Date
Regeneron Pharmaceuticals
Phase 3 research study
Study Type
Expecting 904 study participants
Last Updated